$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

$nmtc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039030 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$629.9K	$466.2K	$36.58K
YoY Change	1865.45%	1174.4%	-4.62%
Cost Of Revenue	$386.2K	$434.7K	$72.81K
YoY Change	904.21%	497.0%	84.98%
Gross Profit	$243.7K	$31.50K	-$36.23K
YoY Change	-3899.56%	-186.95%	3487.13%
Gross Profit Margin	38.68%	6.76%	-99.04%
Selling, General & Admin	$1.862M	$1.821M	$1.818M
YoY Change	21.75%	0.16%	38.45%
% of Gross Profit	764.32%	5780.74%
Research & Development	$1.892M	$1.706M	$1.205M
YoY Change	54.36%	41.56%	11.46%
% of Gross Profit	776.27%	5416.35%
Depreciation & Amortization	$51.38K	$38.33K	$28.53K
YoY Change	98.16%	34.35%	47.9%
% of Gross Profit	21.09%	121.67%
Operating Expenses	$3.754M	$3.527M	$3.024M
YoY Change	36.26%	16.66%	26.26%
Operating Profit	-$3.510M	-$3.496M	-$3.060M
YoY Change	27.12%	14.25%	27.72%
Interest Expense			$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$41.46K	-$26.91K	$1.740K
YoY Change	2324.56%	-1646.55%	-2.25%
Pretax Income	-$3.469M	-$3.523M	-$3.058M
YoY Change	25.69%	15.2%	27.74%
Income Tax
% Of Pretax Income
Net Earnings	-$3.469M	-$3.523M	-$3.058M
YoY Change	25.69%	15.2%	27.74%
Net Earnings / Revenue	-550.68%	-755.69%	-8359.94%
Basic Earnings Per Share	-$0.20	-$0.21	-$0.19
Diluted Earnings Per Share	-$0.20	-$0.21	-$188.9K
COMMON SHARES
Basic Shares Outstanding	17.56M shares	16.36M shares	16.19M shares
Diluted Shares Outstanding	17.58M shares	16.41M shares	16.19M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.083M	$4.598M	$12.87M
YoY Change	-69.71%	-64.27%	14.15%
Cash & Equivalents	$3.083M	$3.602M	$12.87M
Short-Term Investments	$0.00	$995.4K
Other Short-Term Assets	$278.8K	$370.7K	$315.1K
YoY Change	-6.0%	17.65%	288.87%
Inventory	$1.517M	$1.174M	$221.9K
Prepaid Expenses	$278.8K	$370.7K
Receivables		$214.0K	$36.58K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.879M	$6.357M	$13.44M
YoY Change	-55.36%	-52.71%	18.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$586.9K	$522.8K	$523.0K
YoY Change	86.16%	-0.04%	25.57%
Goodwill
YoY Change
Intangibles	$95.16K	$100.7K
YoY Change	-19.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$879.4K	$848.5K	$646.0K
YoY Change	37.04%	31.35%	14.98%
TOTAL ASSETS
Total Short-Term Assets	$4.879M	$6.357M	$13.44M
Total Long-Term Assets	$879.4K	$848.5K	$646.0K
Total Assets	$5.758M	$7.205M	$14.09M
YoY Change	-50.24%	-48.86%	18.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$958.8K	$953.4K	$446.0K
YoY Change	194.99%	113.77%	28.99%
Accrued Expenses	$789.1K	$596.9K	$362.0K
YoY Change	61.95%	64.92%	-3.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.748M	$1.550M	$810.2K
YoY Change	114.59%	91.35%	7.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$88.92K	$121.9K	$156.0K
YoY Change	-35.55%	-21.88%	-49.12%
Total Long-Term Liabilities	$88.92K	$121.9K	$156.0K
YoY Change	-35.55%	-21.88%	-49.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.748M	$1.550M	$810.2K
Total Long-Term Liabilities	$88.92K	$121.9K	$156.0K
Total Liabilities	$1.837M	$1.672M	$966.3K
YoY Change	92.85%	73.07%	-8.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$59.55M	-$56.10M
YoY Change	20.42%
Common Stock	$17.86K	$16.89K
YoY Change	10.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.921M	$5.533M	$13.12M
YoY Change
Total Liabilities & Shareholders Equity	$5.758M	$7.205M	$14.09M
YoY Change	-50.24%	-48.86%	18.22%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.469M	-$3.523M	-$3.058M
YoY Change	25.69%	15.2%	27.74%
Depreciation, Depletion And Amortization	$51.38K	$38.33K	$28.53K
YoY Change	98.16%	34.35%	47.9%
Cash From Operating Activities	-$2.940M	-$3.552M	-$3.222M
YoY Change	11.52%	10.24%	35.37%
INVESTING ACTIVITIES
Capital Expenditures	$139.3K	$175.7K	-$93.32K
YoY Change	-356.85%	-288.28%	4430.1%
Acquisitions
YoY Change
Other Investing Activities	$1.000M	$2.000M
YoY Change
Cash From Investing Activities	$860.7K	$1.824M	-$93.32K
YoY Change	-1687.13%	-2054.9%	4430.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.561M	662.0K	-320.0
YoY Change		-206962.5%	-100.0%
NET CHANGE
Cash From Operating Activities	-2.940M	-3.552M	-3.222M
Cash From Investing Activities	860.7K	1.824M	-93.32K
Cash From Financing Activities	1.561M	662.0K	-320.0
Net Change In Cash	-518.7K	-1.065M	-3.315M
YoY Change	-80.72%	-67.87%	-179.98%
FREE CASH FLOW
Cash From Operating Activities	-$2.940M	-$3.552M	-$3.222M
Capital Expenditures	$139.3K	$175.7K	-$93.32K
Free Cash Flow	-$3.080M	-$3.727M	-$3.128M
YoY Change	19.25%	19.15%	31.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40439
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0863354
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7599 Anagram Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
	dei	City Area Code CityAreaCode	952
	dei	Local Phone Number LocalPhoneNumber	426-1383
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	NMTC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17561776	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3602163	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8160329	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	995432	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	2981010	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	213952	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33237	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1174307	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	704538	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	370703	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	296649	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	6356557	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	12175763	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	100734	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1550386	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3098689	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	121896	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	119556	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111892	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	225005	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	181355	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	522810	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	353599	usd
CY2023Q1	us-gaap	Assets Assets	7205106	usd
CY2022Q3	us-gaap	Assets Assets	12822609	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	953446	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	927662	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	596940	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	715839	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1672282	usd
CY2022Q3	us-gaap	Liabilities Liabilities	3218245	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16887738	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16887738	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16216540	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16216540	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	16888	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	16217	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61598345	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60414959	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56082409	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50826812	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5532824	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7205106	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12822609	usd
CY2023Q1	us-gaap	Revenues Revenues	466176	usd
CY2022Q1	us-gaap	Revenues Revenues	36584	usd
	us-gaap	Revenues Revenues	580755	usd
	us-gaap	Revenues Revenues	70332	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	434673	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	72807	usd
	us-gaap	Cost Of Revenue CostOfRevenue	561559	usd
	us-gaap	Cost Of Revenue CostOfRevenue	119651	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	31503	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	-36223	usd
	us-gaap	Gross Profit GrossProfit	19196	usd
	us-gaap	Gross Profit GrossProfit	-49319	usd
	nmtc	Revenue From Collaboration RevenueFromCollaboration	1455188	usd
	nmtc	Revenue From Collaboration RevenueFromCollaboration	6374	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1821108	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1818207	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3484845	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3560348	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1706314	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1205380	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3269810	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2265842	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	3527422	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	3023587	usd
	us-gaap	Operating Expenses OperatingExpenses	6754655	usd
	us-gaap	Operating Expenses OperatingExpenses	5826190	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3495919	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3059810	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5280271	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5869135	usd
CY2023Q1	us-gaap	Other Income OtherIncome	-26909	usd
CY2022Q1	us-gaap	Other Income OtherIncome	1743	usd
	us-gaap	Other Income OtherIncome	24674	usd
	us-gaap	Other Income OtherIncome	3593	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3522828	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3058067	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5255597	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5865542	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3522828	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3058067	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5255597	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5865542	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16414795	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16189867	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16321891	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15794880	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	6553901	usd
CY2021Q4	nmtc	Issuance Of Warrants In Connections With Convertible Notes Offering IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering	13350582	usd
CY2021Q4	nmtc	Issuance Cost In Connection With Public Offering IssuanceCostInConnectionWithPublicOffering	1352280	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	203072	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-2807475	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	15947800	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	232716	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3058067	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	13122449	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	300181	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1732769	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8171776	usd
CY2023Q1	nmtc	Issuance Of Common Stock In Connection With Atthemarket Offering Program IssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	928257	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-183359	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	237628	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-98650	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3522828	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5532824	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5255597	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5865542	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79799	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	53692	usd
	nmtc	Allocated Share Based Compensation AllocatedShareBasedCompensation	537809	usd
	nmtc	Allocated Share Based Compensation AllocatedShareBasedCompensation	435788	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	41003	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-53886	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-52905	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	180715	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11752	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	469769	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	123616	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	74054	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	163990	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-24862	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	33800	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1669283	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-335516	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7043789	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5900727	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1473419	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	3500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	187206	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	154810	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1839375	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-154810	usd
	nmtc	Proceeds From Issuance Of Common Stock In Connection With Private Placement ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement	928257	usd
	nmtc	Proceeds From Issuance Of Common Stock In Connection With Private Placement ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement	13350582	usd
	nmtc	Deferreds Offering Costs DeferredsOfferingCosts	-183359	usd
	nmtc	Deferreds Offering Costs DeferredsOfferingCosts	-1327300	usd
	nmtc	Share Repurchases For The Payment Of Employee Taxes ShareRepurchasesForThePaymentOfEmployeeTaxes	98650	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	646248	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12023282	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4558166	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5967745	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8160329	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6901346	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3602163	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12869091	usd
	nmtc	Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering	24980	usd
	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease	97536	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	50646	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management’s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	nmtc	Warrantshares Warrantshares	6832865	shares
	nmtc	Warrantshares Warrantshares	6753444	shares
	nmtc	Stock Options StockOptions	1370427	shares
	nmtc	Stock Options StockOptions	1162059	shares
	nmtc	Restricted Stock Unit RestrictedStockUnit	234348	shares
	nmtc	Restricted Stock Unit RestrictedStockUnit	359394	shares
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2020Q3	nmtc	Royalty Minimum Payments Year One RoyaltyMinimumPaymentsYearOne	50000	usd
CY2021Q3	nmtc	Royalty Minimum Payments Year Two RoyaltyMinimumPaymentsYearTwo	100000	usd
CY2022Q3	nmtc	Royalty Minimum Payments Year Three RoyaltyMinimumPaymentsYearThree	150000	usd
	nmtc	Lease Agreement Description LeaseAgreementDescription	The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord’s annual operating expenses associated with the premises, calculated as set forth in the Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.
CY2021Q3	nmtc	Lease Space LeaseSpace	1162	sqm
CY2021Q3	nmtc	Lease Rental Expense LeaseRentalExpense	4241	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2022Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2024-12-31
CY2023Q1	nmtc	Lease Rental Expense LeaseRentalExpense	4453	usd
CY2023Q1	nmtc	Rent Expense RentExpense	43053	usd
	nmtc	Rent Expense RentExpense	85527	usd
CY2022Q1	nmtc	Rent Expense RentExpense	43085	usd
	nmtc	Rent Expense RentExpense	86130	usd
	nmtc	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	66493	usd
	nmtc	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	64871	usd
	nmtc	Operating Leases OperatingLeases	97536	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	225005	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	181355	usd
CY2023Q1	nmtc	Lease Liability LeaseLiability	243980	usd
CY2022Q3	nmtc	Lease Liability LeaseLiability	202895	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078	pure
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.069	pure
CY2023Q1	nmtc	Lessee Operating Lease Liability Payments Due One Year LesseeOperatingLeaseLiabilityPaymentsDueOneYear	102209	usd
CY2023Q1	nmtc	Lessee Operating Lease Liability Payments Due Two Year LesseeOperatingLeaseLiabilityPaymentsDueTwoYear	139969	usd
CY2023Q1	nmtc	Lessee Operating Lease Liability Payments Due Three Year LesseeOperatingLeaseLiabilityPaymentsDueThreeYear	21227	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	263405	usd
CY2023Q1	us-gaap	Receivable With Imputed Interest Net Amount ReceivableWithImputedInterestNetAmount	19425	usd
CY2023Q1	nmtc	Lease Liability Net LeaseLiabilityNet	243980	usd
CY2023Q1	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	122084	usd
CY2023Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	121896	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111892	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11158	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	100734	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	5579	usd
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	11158	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	5579	usd
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	11158	usd
CY2023Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	775913	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	538061	usd
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1895	usd
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1895	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	777808	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	539956	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	254998	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	186357	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	522810	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	353599	usd
CY2023Q1	us-gaap	Depreciation Depreciation	38331	usd
	us-gaap	Depreciation Depreciation	68641	usd
CY2022Q1	us-gaap	Depreciation Depreciation	22952	usd
	us-gaap	Depreciation Depreciation	42534	usd
CY2023Q1	nmtc	Accrued Payroll AccruedPayroll	427356	usd
CY2022Q3	nmtc	Accrued Payroll AccruedPayroll	521368	usd
CY2023Q1	nmtc	Lease Liability Shortterms LeaseLiabilityShortterms	122084	usd
CY2022Q3	nmtc	Lease Liability Shortterms LeaseLiabilityShortterms	83339	usd
CY2023Q1	nmtc	Royalty Payments RoyaltyPayments	37500	usd
CY2022Q3	nmtc	Royalty Payments RoyaltyPayments	111132	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	596940	usd
CY2022Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	715839	usd
	nmtc	Intial Fee Payment IntialFeePayment	2000000	usd
CY2022Q3	nmtc	Milestone Payments Paid MilestonePaymentsPaid	3500000	usd
	nmtc	Aggregate Number Of Warrants Exercisable AggregateNumberOfWarrantsExercisable	350000	shares
CY2023Q1	us-gaap	Share Price SharePrice	3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.029	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.535	pure
	nmtc	Expected Term ExpectedTerm	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	5400000	usd
	nmtc	Initial Exclusivity Fee InitialExclusivityFee	2000000	usd
	nmtc	Milestone Payments MilestonePayments	3500000	usd
	nmtc	Fair Value Of Warrants FairValueOfWarrants	100000	usd
CY2023Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	0	usd
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1455188	usd
CY2022Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	0	usd
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	6374	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
CY2021Q3	us-gaap	Deferred Revenue DeferredRevenue	8622	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1455188	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6374	usd
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	2248	usd
CY2023Q1	nmtc	Product Revenue ProductRevenue	466176	usd
	nmtc	Product Revenue ProductRevenue	580755	usd
CY2022Q1	nmtc	Product Revenue ProductRevenue	36584	usd
	nmtc	Product Revenue ProductRevenue	70332	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	53613	usd
	us-gaap	Advertising Expense AdvertisingExpense	106639	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	113197	usd
	us-gaap	Advertising Expense AdvertisingExpense	174532	usd
CY2023Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	199467	usd
CY2022Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	194874	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	454932	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	357875	usd
CY2023Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	38161	usd
CY2022Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	37842	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	82877	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	77913	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	237628	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	232716	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	537809	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	435788	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	56781	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	60000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	130512	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	62000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.75
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.03
	nmtc	Total Expense Of Stock Option TotalExpenseOfStockOption	323747	usd
	nmtc	Total Expense Of Stock Option TotalExpenseOfStockOption	307782	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1370427	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1239915	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.581	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.535	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.555	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.535	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	212224	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	201060	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	22501	shares
CY2023Q1	nmtc	Aggregate Shares AggregateShares	61728	shares
	nmtc	Aggregate Shares AggregateShares	61728	shares
CY2022Q1	nmtc	Aggregate Shares AggregateShares	355950	shares
	nmtc	Aggregate Shares AggregateShares	355950	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.50	pure
	nmtc	Total Expense Of Restricted Stock Option TotalExpenseOfRestrictedStockOption	214062	usd
	nmtc	Total Expense Of Restricted Stock Option TotalExpenseOfRestrictedStockOption	128006	usd
CY2022Q4	nmtc	Reserved Share ReservedShare	420350	shares
	nmtc	Shares Outstanding Percentage SharesOutstandingPercentage	0.13	pure
	nmtc	Option Plan Shares OptionPlanShares	129479	shares
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1334727	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	One
	nmtc	Contributions Amount ContributionsAmount	30697	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	nmtc	Aggregate Offering Price AggregateOfferingPrice	14500000	usd
CY2022Q4	nmtc	Fixed Commission Rate FixedCommissionRate	0.03	pure
CY2023Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	516484	shares
	nmtc	Gross Proceeds GrossProceeds	928257	usd
	nmtc	Issuance Costs IssuanceCosts	183359	usd
CY2021Q4	nmtc	Issuance Of Shares IssuanceOfShares	3750000	shares
	nmtc	Purchase Of Additional Shares PurchaseOfAdditionalShares	562500	shares
CY2022Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	422057	shares
CY2023Q1	nmtc	Warrants Expired WarrantsExpired	270478	shares
	nmtc	Employees Compensation Percentage EmployeesCompensationPercentage	1	pure
	nmtc	Deferrals Percentage DeferralsPercentage	1	pure
	nmtc	Contributions Percentage ContributionsPercentage	0.03	pure
	nmtc	Internal Revenue Percentage InternalRevenuePercentage	1	pure
CY2023Q1	nmtc	Contributions Amount ContributionsAmount	0	usd
CY2022Q1	nmtc	Contributions Amount ContributionsAmount	0	usd
	nmtc	Contributions Amount ContributionsAmount	30697	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Entity Registrant Name EntityRegistrantName	NEUROONE MEDICAL TECHNOLOGIES Corp
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
	nmtc	Share Repurchases For The Payment Of Employee Taxes ShareRepurchasesForThePaymentOfEmployeeTaxes		usd
	nmtc	Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering		usd
	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease		usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities		usd
	nmtc	Operating Leases OperatingLeases		usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001500198

Files In Submission

Name	View Source	Status
nmtc-20230331_cal.xml	Edgar Link	unprocessable
0001213900-23-039030-index-headers.html	Edgar Link	pending
0001213900-23-039030-index.html	Edgar Link	pending
0001213900-23-039030.txt	Edgar Link	pending
0001213900-23-039030-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_neuroone.htm	Edgar Link	pending
f10q0323ex31-2_neuroone.htm	Edgar Link	pending
f10q0323ex32-1_neuroone.htm	Edgar Link	pending
f10q0323ex32-2_neuroone.htm	Edgar Link	pending
f10q0323_neuroonemedical.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmtc-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmtc-20230331_def.xml	Edgar Link	unprocessable
nmtc-20230331_lab.xml	Edgar Link	unprocessable
nmtc-20230331_pre.xml	Edgar Link	unprocessable
f10q0323_neuroonemedical_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2023 Q2 Form 10-Q Financial Statement

#000121390023039030 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2023 Q2 Form 10-Q Financial Statement

#000121390023039030 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc